Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Dillard's Unlikely to Provide Annual Guidance in Q3 Financial Report, UBS Says

Dillard's Unlikely to Provide Annual Guidance in Q3 Financial Report, UBS Says

MT newswireMT newswire2026/11/03 16:30
12:30 PM EST, 11/03/2026 (MT Newswires) -- Dillard's (DDS) is unlikely to provide annual guidance or Q4 commentary in its Q3 financial report, with the market expected to focus on business trends, UBS analysts said in a Tuesday note. Analysts said that investor expectations for comps to remain stable or modestly accelerate on quarter despite tougher comparisons and modestly bullish sentiment toward Dillard's made them to see a slightly unfavorable upside/downside skew into the print. UBS said the company's "bar" for Q3 is to show improving operating trends, especially comparable sales growth of 1% to 2% relative to 1% in Q2, and gross margin expansion of 25 to 75 basis points versus 45 basis points in Q2. Analysts said Dillard's US search trends rose 5% and online visits were strong in the first two months of the quarter, but noted that observed store sales declined 1.3%. They model Q3 comparable sales growth of 1%. UBS reiterated its sell rating on the stock with a price target of $468 per share. Shares of the company were down over 6% in Tuesday trading. Price: 603.69, Change: -42.47, Percent Change: -6.57
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss